Market Overview:
The global overactive bladder (OAB) therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of OAB, rising geriatric population, and growing awareness about OAB therapies. The anticholinergic agents segment is expected to dominate the global OAB therapeutics market in terms of revenue during the forecast period. However, the beta-3 adrenoreceptor agonists segment is projected to grow at a higher CAGR than any other segment during the forecast period. Geographically, North America dominates the global OAB therapeutics market followed by Europe and Asia Pacific respectively.
 Therapeutics Industry Outlook.svg)
Product Definition:
OAB is a condition that is characterised by the sudden, strong need to urinate. This often leads to people having to go to the toilet very frequently, sometimes up to 60 times a day. OAB can also lead people feeling like they cannot wait long enough before they have to go and results in them going out of their way (e.g., walking around instead of taking the car) or interrupting their sleep in order to use the toilet.
Anticholinergic Agents:
Anticholinergic agents are used to treat bladder control problems such as urinary incontinence, overactive bladder, and pelvic pain. These drugs block the action of acetylcholine, a chemical that facilitates the movement of muscles in the body. Blocking this receptor results in reduced muscle activity in the bladder which ultimately improves urine flow and reduces urine volume.
Beta-3 Adrenoreceptor Agonists:
Beta-3 adrenoreceptor agonists are a class of drugs that modulate the activity of beta-3 adrenoceptors, which are found on nerve cells in the bladder. Some people with overactive bladder (OAB) have very high levels of certain chemicals in their urine. These chemicals can cause pain and pressure in the urinary tract and may lead to frequent urination.
The National Institute for Health.
Application Insights:
The other application segment accounted for the largest share of OAB therapeutics in 2017. Other applications include Urology and neurology. The growing geriatric population, increasing number of people suffering from neurological disorders, and rising incidences of overactive bladder are some factors that may drive the global market during the forecast period.
Urology is estimated to be one of the fastest-growing segments owing to a rise in demand for anticholinergic agents, muscarinic receptor agonists/antagonists (such as detrusor muscle relaxants), sphincteric nerve stimulants (SNSs), antimuscarinic agents (such as antidiarrheal drugs) and urodilators among others. Increasing awareness about OAB symptoms coupled with technological advancements such as development of wearable devices that stimulate muscles has led to an increase in product consumption by Urologic physicians worldwide.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and increasing prevalence of OAB are some factors responsible for its dominance. In addition, introduction of new products such as Benlysta (belimumab) by Bioventus is expected to further boost the growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure and growing patient awareness about treatment options for overactive bladder syndrome. Moreover, availability of generic versions of anticholinergic drugs due to their off-label use may encourage patients suffering from OAB symptoms not only in Asia but also across other regions including North America and Europe.
In 2016 Ucera Therapeutics Inc.
Growth Factors:
- Increasing prevalence of overactive bladder (OAB) due to changing lifestyle and aging population.
- Growing demand for minimally invasive therapies for the treatment of OAB.
- increasing research and development activities for novel therapeutics for the treatment of OAB.
Scope Of The Report
Report Attributes
Report Details
Report Title
Overactive Bladder (OAB) Therapeutics Market Research Report
By Type
Anticholinergic Agents, Beta-3 Adrenoreceptor Agonists
By Application
Hosptial, Clinci, Other
By Companies
Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, Allergan, Sanofi, Tengion, Teva Pharmaceutical Industries
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
189
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Overactive Bladder (OAB) Therapeutics Market Report Segments:
The global Overactive Bladder (OAB) Therapeutics market is segmented on the basis of:
Types
Anticholinergic Agents, Beta-3 Adrenoreceptor Agonists
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hosptial, Clinci, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- Astellas Pharma
- Hisamitsu Pharmaceutical
- Pfizer
- Ferring
- GlaxoSmithKline
- Ion Channel Innovations
- Kwang Dong Pharmaceutical
- Lanzhou Institute of Biological Products
- Merck
- Allergan
- Sanofi
- Tengion
- Teva Pharmaceutical Industries
 Therapeutics Market Overview.svg)
Highlights of The Overactive Bladder (OAB) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anticholinergic Agents
- Beta-3 Adrenoreceptor Agonists
- By Application:
- Hosptial
- Clinci
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Overactive Bladder (OAB) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Therapeutics Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
OAB therapies are medications used to treat overactive bladder (OAB) symptoms. These treatments can include prescription medications, over-the-counter remedies, and surgery.
Some of the key players operating in the overactive bladder (oab) therapeutics market are Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Pfizer, Ferring, GlaxoSmithKline, Ion Channel Innovations, Kwang Dong Pharmaceutical, Lanzhou Institute of Biological Products, Merck, Allergan, Sanofi, Tengion, Teva Pharmaceutical Industries.
The overactive bladder (oab) therapeutics market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Overactive Bladder (OAB) Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Overactive Bladder (OAB) Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Overactive Bladder (OAB) Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Overactive Bladder (OAB) Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Overactive Bladder (OAB) Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Overactive Bladder (OAB) Therapeutics Market Size and Y-o-Y Growth
4.5.2 Overactive Bladder (OAB) Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Anticholinergic Agents
5.2.2 Beta-3 Adrenoreceptor Agonists
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hosptial
6.2.2 Clinci
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Overactive Bladder (OAB) Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Overactive Bladder (OAB) Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Anticholinergic Agents
9.6.2 Beta-3 Adrenoreceptor Agonists
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hosptial
9.10.2 Clinci
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Anticholinergic Agents
10.6.2 Beta-3 Adrenoreceptor Agonists
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hosptial
10.10.2 Clinci
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Anticholinergic Agents
11.6.2 Beta-3 Adrenoreceptor Agonists
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hosptial
11.10.2 Clinci
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Anticholinergic Agents
12.6.2 Beta-3 Adrenoreceptor Agonists
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hosptial
12.10.2 Clinci
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Anticholinergic Agents
13.6.2 Beta-3 Adrenoreceptor Agonists
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hosptial
13.10.2 Clinci
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Overactive Bladder (OAB) Therapeutics Market: Competitive Dashboard
14.2 Global Overactive Bladder (OAB) Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan
14.3.2 Astellas Pharma
14.3.3 Hisamitsu Pharmaceutical
14.3.4 Pfizer
14.3.5 Ferring
14.3.6 GlaxoSmithKline
14.3.7 Ion Channel Innovations
14.3.8 Kwang Dong Pharmaceutical
14.3.9 Lanzhou Institute of Biological Products
14.3.10 Merck
14.3.11 Allergan
14.3.12 Sanofi
14.3.13 Tengion
14.3.14 Teva Pharmaceutical Industries
